On-demand presentation with Catherine McKeen, Site Operational Director & Head of Chemistry at LGC Group & Juergen Mueller, Commercial and Strategic Development Director Oligo-therapeutics at LGC Axolabs
Which GalNAc ligand you want to choose? LGC Nucleic Acid Chemistry (NAC) group enables a novel, modular access to a proprietary GalNAc ligand system without affecting the phosphate backbone of the corresponding oligonucleotide. It takes advantage of the sugar unit (deoxyribose) utilised to naturally fit into the sugar-phosphate backbone, and, beyond, since it is a proprietary technology, it avoids complicated IP negotiations with 3rd parties.
LGC Nucleic Acid Therapeutics unit (NAT) offers multiple conjugation strategies on solid support or post synthesis depending on the respective GalNAc system chosen. Direct access to LGC’s in-house developed GalNAc ligand reduces the burden for external sourcing efforts. A brief introduction of LGC’s NAT group services and LGC’s NAC group products and locations is given.